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Abstract
Objective
To explore the relation between cigarette smoking intensity and bladder cancer aggres-
siveness at first diagnosis.
Methods
Patients diagnosed with urinary bladder cancer (BC) between 1995–2011 under the age of
75 years were retrospectively identified from the Netherlands Cancer Registry and invited
for a study on genetic and lifestyle risk factors for BC. Information on patients’ self-reported
smoking history was retrieved by means of a postal questionnaire. Tumors were stratified
regarding the risk of progression defined by tumor stage and grade. Multinomial logistic
regression was used to analyze the relation between smoking intensity and aggressiveness
of the tumor.
Results
The UBC study population comprised 323 (17.4%) never smokers, 870 (46.8%) former ciga-
rette smokers, and 630 (33.9%) current cigarette smokers. A higher smoking amount was a
risk factor of getting high-risk non-muscle invasive bladder cancer (NMIBC) compared with
low-risk NMIBC in ever and former cigarette smokers (OR: 1.02 per cigarette smoked, 95%
CI: 1.00–1.03 and OR: 1.03, 95% CI: 1.01–1.05, respectively). A statistically significant
dose-response increase in the risk of a more aggressive cancer type (high-risk NMIBC and
MIBC) was observed with increasing smoking duration among former smokers (p for trend
0.035 and 0.008, respectively). No significant association of the evaluated smoking intensity
variables was observed in current smokers. A longer time of smoking cessation correlated
with a lower odds of a more aggressive cancer.
Conclusion
We observed a weak increase in the risk of a more aggressive tumor type with increasing
smoking intensity in former smokers, but this association was absent in current smokers.
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This conflicting result may suggest that there is no strong relation between smoking
intensity and bladder cancer aggressiveness. Analyses of prospective studies with longitudi-
nal smoking assessment may provide a more definitive answer to the research question.
Introduction
Worldwide, urinary bladder cancer (BC) is the fifth most prevalent type of cancer among men,
while it ranks twelfth among women [1]. In high income countries, >90% of all BC are urothe-
lial cell carcinomas (UCC), the remaining mainly being squamous cell, adeno or small cell
carcinomas [2]. BC comprises a heterogeneous group of tumors that arise by different mole-
cular pathways. Relatively benign, low grade papillary tumors are characterized by loss of het-
erozygosity of chromosome 9 and mutations in FGFR3, PIK3CA and STAG2. Muscle-invasive
bladder cancer (MIBC) commonly shows TP53 mutations and RB1 defects. Carcinoma in situ
(CIS) and a small part of the T1 tumors may have the same characteristics as MIBC [2].
Approximately 75% of patients with BC present with a tumor confined to the mucosa or sub-
mucosa of the bladder wall, i.e., non-muscle-invasive bladder cancer (NMIBC), characterized
by a relatively good prognosis but high relapse rate. On the other hand, the 25% of patients
with MIBC (including metastatic disease) are at considerable risk of cancer-specific mortality
[3–5].
Tobacco smoking, occupational exposure to aromatic amines and other carcinogens,
genetic factors, pelvic radiation therapy, and cyclosphosphamide chemotherapy are risk factors
for UCC [6]. Schistosomiasis infection and chronic inflammation secondary to bacterial infec-
tions, indwelling catheters, bladder calculi or chronic bladder outlet obstruction are also risk
factors, although more related to squamous cell carcinoma (SCC) [7,8]. Smoking is recognized
as the most important risk factor for BC and is estimated to account for 50% of all tumors [9].
Tobacco contains multiple carcinogens, such as 4-aminobiphenyl, 2-naphthylamine, and aro-
matic amines which are associated with BC induction in smokers [10]. The risk of bladder can-
cer increases with the number of cigarettes and years smoked [11].
Some studies suggest that a higher intensity of smoking is significantly related to a more
aggressive bladder tumor at diagnosis [12–19], while other studies found no association
between smoking intensity and grade or stage of the tumor [20–28]. Table 1 summarizes the
current evidence on the relation between smoking intensity and tumor characteristics. If a
relation between the amount and duration of smoking and tumor aggressiveness exists, it may
improve the doctor’s ability to identify patients at risk of a more severe tumor type. Also, it
may be one more reason to stimulate counseling for smoking cessation. This study explores
the association between the intensity of smoking and the aggressiveness of UBC at first diagno-
sis in a large population-based BC series from the Netherlands.
Materials and methods
Study population
This study used data from the Nijmegen Bladder Cancer Study (NBCS). This study population
has been described in more detail previously [29]. Briefly, BC patients diagnosed between
1995–2011 under the age of 75 years in the mid-eastern part of the Netherlands were identified
through the Netherlands Cancer Registry (NCR) held by the Netherlands Comprehensive
Cancer Organization (IKNL) and contacted via their treating physicians.
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Table 1. Studies that evaluated the relation between smoking intensity and tumor characteristics.
Article Study
Design
Population Aggressiveness definition Smoking intensity
definition
Main findings Comments
Pietzak et al.
2015 (12)
Historical
cohort study
740 from Pennsylvania
(USA)
Tumor grade (high vs.
low) and stage (Tis, Ta, T1,
T2, T3 e T4). Muscle-
invasive disease.
Non-smokers, light-
smokers (30 pack/years),
and heavy-smokers (>30
pack/years). Criteria for
National Lung Cancer
Screen Trial, age of 55–74
years with30 pack-years
smoking exposure and
<15 years of smoking
cessation
Heavy smokers were also
more likely to have an initial
tumor, which was high grade
with a more advanced
clinical stage. On
multivariate analysis shown
in pack-years smoking
exposure did not remain
significantly associated with
muscle-invasive disease.
Pack-year was associated
with an increased risk
of an initial high-grade
tumor
On multivariate analysis,
meeting screening criteria
was independently
associated with an initial
muscle invasive tumor
and also associated with
an
increased risk of an initial
high-grade.
Rink et al. 2013
(13)
Historical
cohort study
1506 from North
America and Europe
Tumor stage, grade,
lymphovascular invasion
and lymph node
metastasis. pT3 and/or
pN+ as advanced tumor
stage
Cumulative smoking
exposure: Light short-term
smokers ( 20 cig/day
for 20 y), heavy short-
term smokers (>20 cig/
day for 20 y), light long-
term smokers (20 cig/
day for >20 y), and heavy
long-term smokers (>20
cig/day for >20 y).
Duration of smoking
( 10, 11–20, 21–30, or
>30 y). Quantity of
smoking (1–10, 11–20,
21–30, or >30 cig/day.
When ever smokers were
categorized by cumulative
smoking exposure, tumor
stage (p = 0.007), and lymph
node metastasis (p = 0.003)
and lymphovascular invasion
(p = 0.030) differed by
cumulative smoking
exposure. In multivariable
logistic regression analyses,
smoking Duration and
cumulative smoking
exposure were each
significantly associated with
advanced tumor stage after
adjusting for the effects of
age, gender and study center.
van Roekel
et al. 2013 (20)
Prospective
cohort study
1.067 from West
Midlands (UK)
Higher vs. lower T stage,
grade and tumor size
(mean), NMIBC vs. MIBC,
multiplicity vs. solitary
Smoking frequency (g/
day) and cumulative
smoking amount (Kg).
No associations between
smoking intensity measures
and tumor characteristics.
A significant dose-
response relationship was
found between higher
smoking frequency and
lower age at diagnosis.
Chamssuddin
et al. 2013 (14)
Historical
cohort study
300 from Syria Grade: low-grade (G1) vs.
high-grade (G2). Stage:
low-stage (Ta + T1) high-
stage (T2)
Dose: low- (10–29 cig/
day),
moderate- (30–59 cig/day)
and high-dose smokers
(60 cig/day)
Comparing the high-,
moderate- and low-dose
smokers, the high-dose
group had significantly
higher grades and stages
than the other groups. The
difference between
moderate- and low-dose
smokers was
not significant for grade or
stage.
Mitra et al.
2013 (21)
Historical
cohort study
212 from Los Angeles Stage: Non-muscle-
invasive (Ta/ T1/CIS, N−),
muscle-invasive (T2−4, N
−) and nodal metastasis
(any T, N+)
Group 1 (nonsmokers
+ smoker20 cig/day for
30 y), group 2 (smoker
31–40 y + smoker >20
cig/day for  30y) and
group 3 (smoker >40 y)
The distribution of the
smoking intensity group
does not show statistical
differences according to
tumor stage.
Nonsmokers were
combined with light
smokers in group 1 as a
full sensitivity analysis
revealed no substantive
outcome differences
between the two subgroup
Ajili et al. 2013
(22)
Historical
cohort study
81 from Tunisia Multiplicity (single or
multiple). Histological
grade (low, high). Stage
(pTa or pT1). Size (<3 cm
or 3 cm)
Smoking intensity:  60
pack-years vs. >60 pack-
years
There was no association
between smoking intensity
and tumor multiplicity,
grade, stage and size.
(Continued)
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Table 1. (Continued)
Article Study
Design
Population Aggressiveness definition Smoking intensity
definition
Main findings Comments
Jiang et al.
2012 (15)
Case-control
study
1.439 cases and 1,586
controls from Los
Angeles (USA)
Low-grade superficial
tumors (Ta and grade<3)
vs. high grade superficial
tumors (Ta grade 3 and
T1) vs. muscle-invasive
tumors (T2-T4)1.
Daily dose (cig/day) and
duration (years of
smoking).
Compared to non-smokers,
heavy smokers (i.e., >40 cig/
day and >40 years of
smoking) had higher risk of
invasive bladder cancer
(OR = 9.0, 95% CI = 4.8–
16.8) than for low-grade
superficial bladder cancer
(OR = 3.6, 95% CI = 2.3–5.8)
Also a higher risk of
MIBC was found for
higher daily dose and for
longer smoking duration.
Ros et al. 2012
(23)
Prospective
cohort study
468,656 from 10
European countries
Aggressive (T1, CIS or
G3) vs. non-aggressive
(TaG1 or TaG2)
Smoking duration (y) and
lifetime number of
cigarettes (cig/day)
No association between
smoking behavior and
aggressiveness of the tumor
among men. And not
consistent finding in women.
Differences on the
distribution of smoking
behavior among
aggressive or non-
aggressive subgroups
were not tested.
Ouerhani et al.
2009 (24)
Cohort
study
80 from North of Tunisia Superficial (Ta + T1) vs.
Invasive T2. Grade (G1
vs. G2). Tumor Groups
(T1G2 vs. TaG3 + T1G3
vs.T2)
Nonsmoker, smoker of
<40 pack year and smoker
of 40 pack year.
The comparison of pack year
according to tumor stages
and grades does not show
significant statistical
differences.
Serretta et al.
2006 (25)
Prospective
cohort study
474 from Italy Stage (Ta vs. T1). Grade (I
vs. II). Number (single vs.
multiple).
Period of smoking (>20 y
vs. 20 y) and cig/d (>20
vs. 20)
No statistical correlation was
found between period of
smoking and cig/day with
stage, grade and number.
Mohseni et al.
2004 (16)
Case-control
study
185 from Tehran (Iran) High-grade (3) vs. low-
grade (1–2)). Size (small
tumor (<2cm) vs.
moderate (2-5cm) vs. large
(>5cm).
History of smoking (pack-
years).
Cigarette smoking rate was
statistically higher in patients
with high-grade tumors.
Number of cases and
controls not specified.
Persad et al.
1997 (26)
Case-control
study
107 cases and 85 controls
from Bristol (England)
Grade as aggressive (GIII)
vs. non-aggressive (GI and
GII). Stage (Tis, Ta, T1,
T2, T3 and T4)
Pack-year (mean) No evidence that grade and
invasiveness were associated
with greater exposure.
Sturgeon et al.
1994 (17)
Case-control
study
2,982 cases and 5,782
control from
Connecticut, Iowa, Utah,
New Mexico,
metropolitan area of
Atlanta, Detroit, San
Francisco and Seattle
(USA)
Grade (I vs. II vs. III/IV).
Stage (noninvasive (In situ,
confined to mucosa) vs.
confined to submucosa vs.
muscle invasion vs.
extension beyond
bladder.)
Cigarette use: never, ex-
smoker (<20 cig/day or
20 cig/day) and current
smoker (<20 cig/day, 20–
39 cig/day or40 cig/day)
Risk of each stage of bladder
cancer increased with
cigarette smoking, but the
more advanced the stage, the
higher the relative risk.
Grade of bladder cancer at
diagnosis varied little
according to cigarette
smoking.
Within both the non-
invasive and invasive
tumor stratum, cigarette
use was more strongly
associated with low-grade
than high-grade bladder
cancer.
Hayes et al.
1993 (18)
Case-control
study
368 cases and 466
controls from
Massachusetts (USA)
Invasive ( T1) vs.
superficial (Ta and Cis).
<0.5; 0.5–1.4 and 1.5
+ packs of cigarettes per
day.
The higher amount of packs
of cigarettes per day
increases the risk of invasive
cancer.
For superficial tumors,
the risk was elevated for
all tobacco-use levels,
there was no clear dose-
response trend.
Brooks et al.
1992 (27)
Historical
cohort study
2,893 from Missouri
(USA)
Low grade (G1,G2) vs.
high (G3,G4)). Early stage
(Tis, Ta, T1) vs. late (T2,
T3,T4))
Smoking status: never,
former and light (< 1 pack
per day), moderate (1–2
packs per day) heavy (>2
packs per day)
There is no trend toward
higher grade disease as
smoking increased from
light to moderate to heavy.
Late stage cancer: OR = 1.2
(light), OR = 1.6 (moderate)
and OR = 1.7 (heavy) (not
statistically significant
trend).
Jensen et al.
1987 (28)
Case-control
study
790 cases and 389
controls from
Copenhagen and
Frederiksberg (Denmark)
Grade (3–4 vs. 1–2). Stage
(T2-T4 vs. Ta-T1).
Pack-years and pack-year
equivalents.
No association was found
between pack-years and the
characteristics of the tumor
(stage and grade).
(Continued)
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Patients who consented to participate in the study were asked to fill out a lifestyle question-
naire, including questions on education, occupation, medical history, physical activity, and
complete history of smoking. Furthermore, blood samples were collected by Thrombosis Ser-
vice centers, which hold offices in all the communities in the region. The study was approved
by the institutional review board of the Radboud university medical center, Nijmegen, The
Netherlands (CMO Arnhem-Nijmegen).
Smoking assessment
Information on smoking history was obtained via the lifestyle questionnaire. Patients were
asked for their smoking status at recruitment, age at smoking initiation and cessation, number
of cigarettes, pipes and cigars smoked per day and duration of smoking in years. The timing of
smoking cessation with respect to the diagnosis was calculated as age at diagnosis minus age at
cessation. Smoking status at diagnosis was classified as never smoker, former smoker (quitted
>1 year before diagnosis), current smoker (continuing cigarette smoker or quitted 1 year
before diagnosis). The cutoff point of 1 year before diagnosis was chosen for 2 reasons. First,
because we believe that most patients with early symptoms will be diagnosed within a year,
and second because a change in smoking habits in the year before diagnosis will probably not
have any major effect on bladder cancer aggressiveness. Ever smokers were defined as the
combination of former and current smokers. In the current smokers group, only the smoking
period in years before the diagnosis was considered. Smoking amount was evaluated as ciga-
rettes per day. Cumulative smoking exposure (in pack-years) was calculated by multiplying the
cigarette smoking duration and packages per day (20 cigarettes representing one package).
Pipe and/or cigar smoking (5.9% of all patients) was ignored in the main analyses, assuming
that the majority of Dutch pipe and cigar smokers do not inhale the smoke [30].
Outcome assessment
Detailed clinical data concerning age at diagnosis, tumor stage, tumor grade, tumor number
(single or multiple), tumor size (<3cm and 3cm), presence of concomitant CIS, and histo-
logical type were collected through a medical file survey. Tumor stage and grade were recorded
according to the final conclusion in the pathology report. Tumors with WHO 1973 differentia-
tion grade 1 or 2, WHO/ISUP 2004 low grade, or Malmstro¨m (Modified Bergkvist) grade 1 or
2a were considered low-grade tumors. We classified tumors with WHO 1973 differentiation
grade 3, WHO/ISUP 2004 high grade, or Malmstro¨m (Modified Bergkvist) grade 2b or 3 as
high-grade [31,32]. Tumor aggressiveness was classified according to the risk of progression as
follows: low-risk NMIBC (low-grade Ta tumors), high-risk NMIBC (all stage T1 tumors, all
high-grade tumors, or CIS) and MIBC (stage T2 or any stage withN1 and/or M1) [33].
Table 1. (Continued)
Article Study
Design
Population Aggressiveness definition Smoking intensity
definition
Main findings Comments
Morrison et al.
1982 (19)
Historical
cohort study
762 from Greater Boston,
Massachusetts, USA, 583
from part of Greater
Manchester County, UK,
and 348 from
metropolitan Nagoya,
Japan.
Grade (0-I vs. II vs. III). Current smokers: <1
packs/day vs. 1 pack/day
vs. 2+ packs/day.
The percentage of grade-III
tumors among current
smokers in each area
increased irregularly with the
amount smoked (packs/day).
Cigarette smoking was
not consistently related to
histologic type
https://doi.org/10.1371/journal.pone.0194039.t001
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Statistical analysis
Patient and tumor characteristics were compared between the smoking status categories using
chi-square, Fisher exact, and one-way analysis of variance (ANOVA) tests where appropriate.
Because it is generally believed that there is no ‘no effect level’ in the relation between smoking
and the risk of cancer, we analyzed the dose of smoking using continuous variables. The dis-
tribution of continuous smoking variables was compared between the categories of tumor
multiplicity and tumor aggressiveness and tested for statistical significance using the non-
parametric Kruskal-Wallis test. Multinomial logistic regression was used to analyze the rela-
tion between smoking intensity and aggressiveness of the tumor with adjustment for gender
and age at diagnosis. Low-risk NMIBC was considered as the reference group. We repeated
similar analyses for tumor multiplicity as the dependent variable using solitary tumors as the
reference group. The association of each smoking intensity variable (smoking amount, smok-
ing duration and cumulative smoking exposure), age at smoking initiation, and time since
smoking cessation was assessed separately in ever, former and current smokers. Statistical
analysis was performed using IBM SPSS Statistics for Windows 20 (IBCM Corp., Armonk,
NY, USA) with a p value< 0.05 indicating statistical significance. The data have been made
publicly available thru the Data Archiving and Networked Services (DANS-EASY) and can be
accessed via the link http://dx.doi.org/10.17026/dans-2a6-ate2.
Results
A total of 1859 BC patients were included in the study. The majority of the patients were men
(81.1%). The mean age at diagnosis (SD) was 62.4 (±9.7). Never cigarette smokers represented
323 (17.4%) of all patients, former cigarette smokers 870 (46.8%), and current cigarette smok-
ers, 630 (33.9%). Of all patients, only 40 had a non-UCC histology. Because their smoking dis-
tribution was quite similar (Never 25%, Former 40% and Current 30%) to that of the UCC
patients, we decided not to exclude these 40 patients. A comparison of patient and tumor char-
acteristics by smoking status is shown in Table 2. The groups differ from each other in age at
diagnosis, gender, history of cigar or pipe smoking and tumor stage.
Table 3 shows the distribution of smoking variables in different tumor aggressiveness
groups and different tumor multiplicity groups, by smoking group. In former cigarette smok-
ers, there is a significant difference in the smoking amount, smoking duration and cumulative
smoking in the subgroups of aggressiveness. The median of smoking amount is higher in the
high-risk NMIBC compared with low-aggressive NMIBC, but lower in MIBC. In former
smokers, smoking duration is highest in patients with MIBC and lowest in patients with low
risk NMIBC. The median time since smoking cessation was highest in patients with low-risk
NMIBC and lowest in patients with MIBC. In ever and current cigarette smokers, there was no
difference in the distribution of smoking variables between the subgroups of aggressiveness.
There doesn’t seem to be a strong correlation between smoking and tumor multiplicity. If any-
thing, only current smokers may have more frequently solitary tumors.
In multinomial regression analyses with adjustment for age at diagnosis and gender
(Table 4), smoking amount was a risk factor of getting high-risk NMIBC compared with low-
risk NMIBC in ever and former cigarette smokers (OR: 1.02 per cigarette smoked a day, 95%
CI: 1.00–1.03 and OR: 1.03, 95% CI: 1.01–1.05, respectively). Smoking duration was a risk fac-
tor for MIBC compared with low-risk NMIBC in ever and former cigarette smokers (OR per
year smoked: 1.01, 95% CI: 1.00–1.03 and OR: 1.02, 95% CI: 1.00–1.04, respectively). Time
since smoking cessation was a protective factor in both comparisons, i.e., a longer time of
smoking cessation leads to a lower odds of a more aggressive cancer. Smoking intensity vari-
ables were not significantly related to tumor aggressiveness in current cigarette smokers. By
Smoking intensity and bladder cancer aggressiveness
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Table 2. Baseline characteristics of study population.
N (%) Total
population
(n = 1,859)
Never cigarette smokers
(n = 323)
Former cigarette smokers
(n = 870)
Current cigarette smokers
(n = 630)
Unknown smoking
status
(n = 36)
p value1
Age at diagnosis
(mean ± SD)
62.4 ±9.7 61.5±11.3 65.1±8.3 59.0±9.5 66.9±8.3 <0.001
Gender <0.001
Male 1,507
(81.1)
215 (66.6) 757 (87.0) 503 (79.8) 32 (88.9)
Female 352 (18.9) 108 (33.4) 113 (13.0) 127 (20.2) 4 (11.1)
Type of tobacco <0.001
Ever cigar and/or pipe
smoker
369 (20.2) 109 (33.7) 170 (19.6) 85 (13.5) 5 (71.4)
Never cigar and/or pipe
smoker
1458 (79.8) 214 (66.3) 697 (80.4) 545 (86.5) 2 (28.6)
Missing 32 0 3 0 29
Tumor stage 0.036
0a 1,052
(57.4)
187 (59.0) 489 (57.1) 359 (57.7) 17 (47.2)
0is 59 (3.2) 13 (4.1) 27 (3.2) 16 (2.6) 3 (8.3)
I 400 (21.8) 68 (21.5) 208 (24.3) 117 (18.8) 7 (19.4)
II/III/IV 322 (17.6) 49 (15.5) 134 (15.6) 130 (20.9) 9 (25.0)
Missing 26 6 12 8 0
Concomitant CIS 0.341
No 1614 (88.1) 284 (89.3) 744 (87.0) 555 (89.2) 31 (86.1)
Yes 217 (11.9) 34 (10.7) 111 (13.0) 67 (10.8) 5 (13.9)
Missing 28 5 15 8 0
Tumor grade2 0.074
Low-grade 979 (54.1) 173 (55.4) 438 (51.4) 350 (57.3) 18 (52.9)
High-grade 830 (45.9) 139 (44.6) 414 (48.6) 261 (42.7) 16 (47.1)
Missing 50 11 18 19 2
Tumor number 0.256
Single 1,030
(59.7)
179 (60.9) 466 (57.6) 364 (61.8) 21 (65.6)
Multiple 694 (40.3) 115 (39.1) 343 (42.4) 225 (38.2) 11 (34.4)
Missing 135 29 61 41 4
Tumor size 0.379
< 3cm 377 (75.1) 60 (73.2) 171 (72.8) 139 (78.5) 7 (87.5)
 3cm 125 (24.9) 22 (26.8) 64 (27.2) 38 (21.5) 1 (12.5)
Missing 1,357 241 635 453 28
Histological type 0.126
UCC 1,808(97.8) 310 (96.9) 848 (98.1) 616 (98.1) 34 (94.4)
SCC 17 (0.9) 5 (1.6) 7 (0.8) 5 (0.8) 0 (-)
AC 9 (0.5) 4 (1.2) 1 (0.1) 3 (0.5) 1 (2.8)
Other 14 (0.8) 1 (0.3) 8 (0.9) 4 (0.6) 1 (2.8)
Missing 11 3 6 2 0
1 P value is based on chi-square, Fisher exact, or one-way ANOVA test, where appropriate.
2 Tumors with WHO 1973 differentiation grade 1 or 2, WHO/ISUP 2004 low grade, or Malmstro¨m (Modified Bergkvist) grade 1 or 2a were considered low-grade
tumors. Tumors with WHO 1973 differentiation grade 3, WHO/ISUP 2004 high grade, or Malmstro¨m (Modified Bergkvist) grade 2b or 3 as high-grade
Missing data were not included in the calculation of p values. Abbreviations: N: number of patients; SD: standard deviation; CIS: carcinoma in situ; UCC: urothelial cell
carcinoma; SCC: Squamous cell carcinoma; AC: Adenocarcinoma.
https://doi.org/10.1371/journal.pone.0194039.t002
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Table 3. Distribution of cigarette smoking habits according to tumor aggressiveness and tumor multiplicity at first diagnosis.
All urinary bladder cancer
(n = 1,859)1(Median (Q3-Q1); N
missing)
Low-risk NMIBC
(n = 867) (Median
(Q3-Q1))
High- risk
NMIBC (n = 646)
(Median (Q3-Q1))
MIBC
(n = 322)
(Median (Q3-
Q1))
p value2 Solitary
(n = 1,009)
(Median (Q3-
Q1))
Multiple
(n = 683)
(Median (Q3-
Q1))
p
value2
Smoking status <0.0013 0.2564
Never cigarette
smokers (%)
323 (17.7) 154 (18.1) 115 (18.1) 49 (15.7) 179 (17.7) 115 (16.8)
Ever cigarette
smokers (%)
1500 (82.3) 698 (81.9) 519 (81.9) 264 (84.3) 830 (82.3) 568 (83.2)
Smoking amount
(cig/day)
15 (20–10);8 15 (20–10) 15 (20–10) 15 (20–10) 0.142 15 (20–10) 15 (20–10) 0.314
Smoking
duration (y)
32 (42–20);85 32 (42–20) 31 (40–20) 35 (43–23) 0.055 33 (42–20) 31 (41.8–21) 0.683
Cumulative
smoking (pack-
years)
22.5 (35–12);91 22.4 (34.5–10.5) 23 (35.9–13) 22.5 (36–12.5) 0.363 22.5 (36–12) 23 (34–12.6) 0.583
Age at initiation
(y)
16 (18–15):3 16 (18–15) 16 (18–15) 16 (18–15) 0.870 16 (18–15) 17 (18–15) 0.121
Former cigarette
smokers (%)
870 (47.7) 386 (45.3) 340 (53.6) 134 (42.8) 466 (46.2) 343 (50.2)
Smoking amount
(cig/day)
15 (20–10); 7 14 (20–10) 15 (20–10) 11.5 (20–8) 0.008 15 (20–10) 15 (20–10) 0.259
Smoking
duration (y)
26 (37–17); 39 25 (35–15) 27 (37–18.3) 29.5 (40–19) 0.007 25 (36.3–16.8) 26 (37–18) 0.381
Cumulative
smoking (pack-
years)
18 (30–8.8); 44 16 (26.3–7.4) 20 (31.8–10.2) 18.375 (29.8–
8.4)
0.003 16 (27.8–7.5) 18.9 (30–9.6) 0.112
Age at initiation
(y)
17 (18–15); 2 17 (18–15) 16 (18–15) 17 (19–15) 0.231 17 (18–15) 17 (18–15) 0.566
Time since
smoking
cessation (y)5
18 (26–10); 0 19 (28–11) 17 (24.75–10) 15.5 (24–9) 0.034 17 (26–9) 18 (26–11) 0.354
Current cigarette
smokers (%)
630 (34.6) 312 (36.6) 179 (28.2) 130 (41.5) 364 (36.1) 225 (32.9)
Smoking amount
(cig/day)
15 (20–10); 1 15 (20–10) 15 (20–10) 15 (20–10) 0.783 15 (20–10) 15 (20–10) 0.002
Smoking
duration (y)6
40 (47–30); 46 40 (48–30) 40 (47–30) 39.5 (47–31) 0.859 40 (47–32) 39 (48–30) 0.701
Cumulative
smoking (pack-
years)6
28.5 (40.8–19); 47 29 (41.4–19.4) 27 (40.5–18.4) 27 (39.9–18.1) 0.728 30.6 (41.3–20) 26 (39–16.3) 0.024
Age at initiation
(y)
16 (18–15);1 16 (18–15) 16 (18–15) 16 (18–15) 0.173 16 (18–15) 16 (18–15) 0.117
1 Missing tumor aggressiveness in 24 patients, missing tumor multiplicity in 135 patients and missing smoking status in 36 patients.
2 P value is based on non-parametric Kruskal-Wallis one-way ANOVA test.
3 The distribution of smoking status is significantly different between the three tumor aggressiveness groups (based on chi-square test)
4The distribution of smoking status is not significantly different between the two tumor multiplicity groups (based on chi-square test)
5 Time elapsed since smoking cessation was calculated as the difference between the age at diagnosis and reported age at cessation.
6 Corrected for number of smoking years after diagnosis.
Abbreviations: NMIBC: non-muscle-invasive bladder cancer; MIBC: muscle-invasive bladder cancer; Q1: first quartile; Q3: third quartile; cig/day: cigarettes per day; y:
years.
https://doi.org/10.1371/journal.pone.0194039.t003
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contrast, only in current smokers there seems to be an association between smoking duration
and tumor multiplicity suggesting that a longer smoking history leads to a higher risk of soli-
tary tumors.
Table 5 presents the results from multinomial logistic regression after including smoking
duration as a categorical instead of continuous variable. A longer smoking duration is associ-
ated with higher risks of MIBC compared with low-risk NMIBC mostly in ever and former cig-
arette smokers (p value for trend: 0.004 and 0.008, respectively). Comparing high-risk NMIBC
with low-risk NMIBC, there is a higher odds ratio with increasing smoking duration until 30
years. Thereafter, the risk remains the same or even decreases. In former smokers, there is a
significantly increasing trend (p value: 0.035).
Discussion
The present study was performed with the goal of examining the association between smoking
intensity and tumor aggressiveness. Different aspects of smoking intensity were evaluated such
as smoking amount in cigarettes per day, smoking duration and cumulative smoking in pack-
years. Significant but weak positive associations were found in ever cigarette smokers concern-
ing smoking amount and smoking duration. When the ever cigarette smokers were separated
in former and current cigarette smokers, inconsistent results were found. In the subgroup of
former cigarette smokers, the same relations were found as in ever cigarette smokers, but in
the subgroup of current cigarette smokers no clear relation was found. Apparently, the results
Table 4. Multivariable regression analyses of smoking intensity in relation to tumor aggressiveness and tumor multiplicity.
High- risk NMIBC vs. low- risk NMIBC
(OR (95% CI))1
p value MIBC vs. low- risk NMIBC (OR
(95% CI))1
p value Multiple vs. Solitary (OR
(95% CI))1
p value
Smoking status
Ever cigarette smokers
Smoking amount (cig/day) 1.02 (1.00–1.03) 0.019 1.00 (0.99–1.02) 0.871 1.00 (0.98–1.01) 0.541
Smoking duration (y)3 1.00 (1.00–1.01) 0.487 1.01 (1.00–1.02) 0.036 1.00 (0.99–1.00) 0.229
Cumulative smoking (pack-
years)3
1.00 (1.00–1.01) 0.306 1.01 (1.00–1.01) 0.271 1.00 (0.99–1.00) 0.302
Age at initiation (y) 1.00 (0.97–1.03) 0.732 0.99 (0.95–1.03) 0.535 1.02 (0.99–1.05) 0.134
Former cigarette smokers
Smoking amount (cig/day) 1.03 (1.01–1.05) 0.002 1.01 (0.98–1.03) 0.588 1.01 (0.99–1.02) 0.317
Smoking duration (y) 1.01 (1.00–1.03) 0.083 1.02 (1.00–1.04) 0.027 1.00 (0.99–1.01) 0.795
Cumulative smoking (pack-
years)
1.01 (1.01–1.02) 0.003 1.01 (1.00–1.02) 0.134 1.00 (1.00–1.01) 0.416
Age at initiation (y) 0.97 (0.92–1.02) 0.185 0.96 (0.91–1.02) 0.223 1.01 (0.97–1.05) 0.677
Time since smoking
cessation (y)2
0.98 (0.97–0.99) 0.006 0.97 (0.96–0.99) 0.006 1.00 (0.99–1.02) 0.682
Current cigarette smokers
Smoking amount (cig/day) 0.99 (0.97–1.02) 0.525 0.99 (0.96–1.02) 0.646 0.96 (0.94–0.99) 0.005
Smoking duration (y)3 0.99 (0.97–1.01) 0.435 1.00 (0.98–1.03) 0.873 0.99 (0.97–1.01) 0.140
Cumulative smoking (pack-
years)3
1.00 (0.98–1.01) 0.506 1.00 (0.98–1.01) 0.710 0.99 (0.98–1.00) 0.015
Age at initiation (y) 1.02 (0.98–1.06) 0.425 1.00 (0.96–1.05) 0.895 1.03 (1.00–1.07) 0.085
1 Adjusted for age at diagnosis (continuous) and gender.
2 Time elapsed since smoking cessation was calculated as the difference between the age at diagnosis and reported age at cessation.
3 Corrected for number of smoking years after diagnosis.
Abbreviations: NMIBC: non-muscle-invasive bladder cancer; MIBC: muscle-invasive bladder cancer; cig/day: cigarettes per day; y: years.
https://doi.org/10.1371/journal.pone.0194039.t004
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in ever smokers were driven by those in former smokers only. In the analyses of tumor multi-
plicity the reverse was seen. Only in current smokers, there was a significantly lower risk of
multiple tumors with a longer smoking history.
Among ever smokers, smoking amount was a significant risk factor for high-risk NMIBC
compared with low-risk NMIBC, but not for MIBC compared with low-risk NMIBC. The
same holds true with smoking duration among ever and former smokers and cumulative
smoking in former smokers. These conflicting results suggest that the relation between smok-
ing intensity and tumor aggressiveness is probably weak or even just a chance finding. Previ-
ous studies [20–28] showed no dose-response relations between tumor characteristics and
smoking intensity, supporting our findings.
Jiang et al. [15] combined tumor grade and stage to classify tumor aggressiveness and
found that the risk of more advanced tumors was positively associated with smoking duration
and smoking intensity. Unfortunately, the authors did not make a distinction between former
and current cigarette smokers like we did.
In our study, a longer time of smoking cessation was associated with a lower risk of an
aggressive bladder cancer. In contrast, Jiang et al. [15] showed that an increasing number of
years since quitting leads to a decreased risk of UBC, but there was no difference among sub-
groups of tumor aggressiveness.
Table 5. Multivariable regression analyses of smoking duration in relation to tumor aggressiveness.
N (%) High-risk NMIBC vs. Low-risk NMIBC (OR (95% CI))1 p value MIBC vs. Low-risk NMIBC (OR (95% CI))1 p value
Smoking status
Ever cigarette smokers
Smoking duration2, 3 0.871 0.004
<10 years (ref) 84 (5.9) 1 - 1 -
10-<20 years 211 (14.9) 1.47 (0.82–2.63) 0.192 1.55 (0.70–3.40) 0.280
20-<30 years 299 (21.1) 1.72 (0.98–3.00) 0.057 1.71 (0.80–3.66) 0.166
30-<40 years 359 (25.4) 1.73 (1.00–2.99) 0.051 2.10 (1.00–4.41) 0.050
40 years 462 (30.8) 1.32 (0.76–2.28) 0.328 2.42 (1.16–5.06) 0.018
Former cigarette smokers
Smoking duration3 0.035 0.008
<10 years (ref) 74 (8.9) 1 - 1 -
10-<20 years 174 (20.9) 1.54 (0.83–2.84) 0.172 1.68 (0.70–4.07) 0.248
20-<30 years 223 (26.8) 1.81 (0.99–3.31) 0.054 1.90 (0.79–4.52) 0.150
30-<40 years 197 (23.7) 2.05 (1.11–3.81) 0.023 1.92 (0.79–4.70) 0.152
40 years 163 (19.6) 2.00 (1.03–3.86) 0.039 3.29 (1.33–8.10) 0.010
Current cigarette smokers
Smoking duration2, 3 0.920 0.353
<10 years (ref) 10 (1.6) 1 - 1 -
10-<20 years 37 (6.3) 1.47 (0.25–8.72) 0.673 1.11 (0.18–6.88) 0.912
20-<30 years 76 (13.0) 2.16 (0.40–11.68) 0.373 1.05 (0.19–5.85) 0.960
30-<40 years 162 (27.7) 1.95 (0.38–10.15) 0.428 1.57 (0.30–8.23) 0.597
40 years 299 (51.2) 1.48 (0.28–7.82) 0.645 1.51 (0.28–8.25) 0.631
1 Adjusted for age at diagnosis (continuous) and gender.
2 Corrected for number of smoking years after diagnosis.
3 p value for trend
NMIBC: non-muscle-invasive bladder cancer; MIBC: muscle-invasive bladder cancer; y: years.
https://doi.org/10.1371/journal.pone.0194039.t005
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FGFR3 mutations are associated with low-grade and low-stage tumors while TP53 muta-
tions are associated with high-grade and high-stage tumors [2,34]. If smoking leads to different
mutations in these or other stage-related genes, then it would be logical to find an association
between smoking and disease aggressiveness. It has been shown in lung cancer, based on data
from The Cancer Genome Atlas (TCGA), that smoking induces specific gene mutations [35].
However, this does not seem to be the case in bladder cancer. In The Cancer Genome Atlas
there was no statistically significant association between smoking status and the mutational
spectrum, frequency of mutation in any significantly mutated gene, occurrence of focal
somatic CNAs or expression subtype in 131 muscle invasive bladder cancers (although it is not
clear from the paper how ‘smoking’ was phenotyped). However, a major subtype of MIBC
(‘CIMP’) was identified by unsupervised cluster analysis that has high-level promoter hyper-
methylation associated with the number of pack-years smoking [36]. In a follow-up paper
describing a larger number of tumors (N = 409) somewhat more ERCC2 signature mutations
are found among smokers [37]. A small study from Canada showed that TP53 mutations are
more common with increasing years of smoking, although not more common with increasing
numbers of cigarettes smoked [38].
McConkey et al. [39] and other groups have recently suggested a new molecular subclassifi-
cation of bladder cancer related with distinct patterns of progression and response to conven-
tional chemotherapy. It is possible that this new classification is stronger related to the
intensity of smoking. Indeed, in a recent study, again based on TCGA, it was shown that
patients with the more aggressive basal-like subtypes, started smoking earlier than patients
with a luminal subtype [40]. Unfortunately, we were unable to examine this in our study.
A strength of the present paper is its large sample size. A weakness is that the NBCS had a
retrospective design which means that prevalent cases were recruited for the study. Especially
patients with more severe disease may have deceased prior to recruitment. The time lag
between diagnosis and study enrollment was up to 12 years. The absence of prevalent patients
that failed to survive until the sampling date has resulted in a study population biased towards
favorable tumor aggressiveness. In theory, this may have biased the effect size estimates and
thereby the ability of our study to identify any relation between smoking and tumor aggres-
siveness. For that reason, we repeated our analyses using only the subset of our patient cohort
with a maximum time between diagnosis and study enrollment of 3 years (approximately 50%
of the series). This analysis showed only marginal differences with the results using the whole
series.
If there is a shorter diagnostic delay among smokers, it might cause a bias towards an asso-
ciation between smoking and a more favorable disease stage. In The Netherlands, there is no
screening or active case finding for bladder cancer. In the case of unexplained macroscopic
hematuria, the guidelines dictate that bladder cancer should be ruled out. We believe that the
adherence to this guideline is very good in men, irrespective of their smoking status. It is gen-
erally known that the diagnostic delay is somewhat longer in women. We cannot rule out that
smoking habits may have influenced this diagnostic delay in some women.
In theory, our study may have suffered from differential misclassification if patients with a
more aggressive tumor reported their smoking habits in a different way than patients with a
less aggressive tumor. Unfortunately, there is no way to check this. Of course, there will have
been a certain degree of non-differential misclassification of smoking habits. Also, we did not
collect information on, e.g., the use of filter cigarettes, depth of inhaling, brand of the cigarette,
and passive smoking. It is impossible to capture all of these differences but a prospective design
with serial measurements may lead to less misclassification compared to the single retrospec-
tive measurement in our study.
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For a large percentage of patients, tumor size was missing due to a lack of information in
the medical records. This prohibited us to evaluate an association between smoking intensity
and this characteristic.
Among former cigarette smokers, larger smoking amount and longer smoking duration are
weakly related with a more aggressive cancer but no relation was found among current
smokers.
This inconsistency may suggest that there is no strong relation between smoking intensity
and aggressiveness of the tumor. However, the retrospective design of the study may have
influenced the results to some extent. Analyses of prospective studies with longitudinal smok-
ing assessment might answer the research question in a more definitive way.
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